ACME UNITED CORP - 10-Q Summary (Period Ended June 30, 2026)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ACME UNITED CORP for the period ended June 30, 2026. The Company manufactures and sells first aid, medical, cutting, and sharpening products. Operations are reported in three segments: United States, Canada, and Europe. The Company is an Accelerated Filer and a Smaller Reporting Company.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Net Sales | $62.7 million | $115.0 million |
| Gross Profit | $26.7 million (42.6% margin) | $47.5 million (41.3% margin) |
| Operating Income | $6.8 million | $8.6 million |
| Net Income | $5.1 million | $6.0 million |
| Diluted EPS | $1.22 | $1.46 |
| Cash from Operations (6mo) | $10.9 million | |
| Long-Term Debt | $22.6 million (Revolving) + $9.2 million (Mortgage) | |
| Working Capital | $77.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 16% (QTD) and 15% (YTD) compared to 2025. Organic growth was 8% (QTD) and 7% (YTD), with the remainder driven by the acquisition of "My Medic" assets.
- Segment Performance:
- U.S.: Sales up 17% (QTD) and 15% (YTD). Operating income decreased slightly due to tariff impacts on inventory sold.
- Europe: Sales up 24% (QTD) and 28% (YTD), driven by e-commerce and a German acquisition.
- Canada: Sales up 1% (QTD) and 7% (YTD).
- Profitability: Gross margin improved to 42.6% (QTD) from 41.0% in 2025, aided by the My Medic business. However, operating income for the six months decreased slightly ($8.6M vs $8.8M) due to higher costs of sales and SG&A expenses related to the new DTC business and tariff costs.
- Balance Sheet: Total assets increased to $200.6 million from $171.0 million, primarily due to the acquisition of My Medic intangible assets ($15.4M) and increased receivables/inventory.
Guidance, Outlook, and Risks
- Acquisition Integration: The Company acquired My Medic (tactical/trauma products) for $18.5 million in January 2026. My Medic is seasonal, with profitability concentrated in Q4.
- Debt Refinancing: On July 15, 2026 (subsequent event), the Company entered a new $65 million syndicated credit facility expiring in 2029, replacing the prior facility. The opening balance was $28.5 million.
- Tariffs and Supply Chain: The Company recognized tariff expenses in the first half of 2026 on inventory purchased under 2025 rates. Management expects tariff impacts to lessen in the second half of 2026 as lower-rate inventory is sold. Risks include ongoing geopolitical tensions (Middle East, Ukraine) and potential new tariffs on Chinese goods.
- Liquidity: The Company maintains a current ratio of 3.23 and believes cash flows and credit facilities are sufficient for the next 12 months.
Investor Verification Checklist
- My Medic Integration: Verify the revenue contribution and profitability timeline of the My Medic acquisition, noting its seasonal Q4 bias.
- Tariff Exposure: Confirm the extent of remaining inventory subject to high 2025 tariff rates versus new lower-rate inventory.
- Debt Covenants: Review compliance with the new credit facility covenants (Max Net Funded Debt/EBITDA of 3.75x; Min Fixed Charge Coverage of 1.10x).
- Contingent Consideration: Monitor the $1.0 million revenue milestone payment due by Dec 31, 2027, and the $3.1 million holdback for indemnification claims.
- Working Capital Trends: Analyze the $9.6 million increase in accounts receivable and $4.2 million increase in working capital to ensure collection efficiency remains stable.